Please login to the form below

Not currently logged in
Email:
Password:

Sanofi vaccine fast-tracked

Sanofi Pasteur has been granted fast-track status by the US Food and Drug Administration for its investigational C. difficile vaccine candidate

Sanofi Pasteur, the vaccines unit of sanofi-aventis (S-A), has been granted fast-track status by the US Food and Drug Administration (FDA) for its investigational Clostridium difficile vaccine candidate. The vaccine, which is in phase II development, is intended to prevent Clostridium difficile infection, which is one of the most common infections acquired in hospitals in North America and Europe.

Sanofi estimates that there are about 500,000 cases of CDI every year in the US, costing the healthcare system more than $3bn annually.  The problem is only likely to worsen, due to the recent emergence of a hyper-virulent strain of C. difficile, according to the company.

The FDA's fast-track programme is designed to speed the development and review of new drugs and vaccines that treat or prevent serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Under the programme, companies can submit portions of the marketing application to the FDA for review as they are completed.

In addition, the sponsor company of a fast-tracked drug or vaccine is eligible for more frequent meetings and written correspondence with the FDA, and the product candidate is generally eligible for an accelerated approval, which is an approval based on surrogate endpoints.

10th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics